Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Saturn Oil & Gas Inc. Announces its First Development of Cardium Wells at Brazeau and Continued Successful Development (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Indaptus Therapeutics Inc INDP

Healthcare Biotechnology
Indaptus Therapeutics, Inc. is a clinical-stage biotechnology company, which specializes in cancer and viral infection treatments. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be... see more

Recent & Breaking News (NDAQ:INDP)

Indaptus Therapeutics to Present at the Jefferies Healthcare Conference 2023

GlobeNewswire May 31, 2023

Indaptus Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire May 11, 2023

Following Granting of Indian Patent, Indaptus Therapeutics Achieves Patent Protection in 32 Countries for Decoy Immunotherapy Platform

GlobeNewswire May 9, 2023

Indaptus Therapeutics' Chief Scientific Officer Michael Newman, Ph.D. Named a Chair of the 4th STING & TLR-Targeting Therapies Summit

GlobeNewswire May 1, 2023

Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023

GlobeNewswire April 20, 2023

UPDATE -- Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

GlobeNewswire April 19, 2023

Indaptus Therapeutics Presents Data Demonstrating Preclinical Efficacy of Decoy, its Bacteria-Based Immunotherapy Platform Technology, at the American Association for Cancer Research Conference 2023

GlobeNewswire April 19, 2023

Indaptus Therapeutics Receives Brazilian Patent Allowance for Decoy Platform

GlobeNewswire April 17, 2023

Indaptus Therapeutics to Present at the Investor Summit Conference

GlobeNewswire March 22, 2023

Indaptus Therapeutics Reports Fourth Quarter and Year-End 2022 Financial Results and Provides Corporate Update

GlobeNewswire March 17, 2023

Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023

GlobeNewswire March 15, 2023

Indaptus Therapeutics Activates Emory Winship Cancer Institute as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

GlobeNewswire March 13, 2023

Indaptus Therapeutics Doses First Subject in its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

GlobeNewswire March 7, 2023

Indaptus Therapeutics Names Robert Martell, M.D., Ph.D. to its Board of Directors

GlobeNewswire February 14, 2023

Indaptus Therapeutics Activates Morristown Medical Center as Trial Site in INDP-D101, Its Ongoing Phase 1 Open Label Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

GlobeNewswire February 7, 2023

Indaptus Therapeutics Announces Initiation of First-In-Human, Open Label, Dose Escalation and Expansion Multicenter Phase 1 Clinical Trial of Decoy20 in Patients with Advanced Solid Tumors

GlobeNewswire December 13, 2022

Indaptus Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire November 10, 2022

Indaptus Therapeutics to Present at the LD Micro Main Event XV

GlobeNewswire October 18, 2022

Indaptus Therapeutics to Present at the 24th Annual H.C. Wainwright Global Investment Conference

GlobeNewswire September 6, 2022

Indaptus Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update

GlobeNewswire August 8, 2022